Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology

Ajani, Jaffer A.; D’Amico, Thomas A.; Almhanna, Khaldoun; Bentrem, David J.; Chao, Joseph; Das, Prajnan; Denlinger, Crystal S.; Fanta, Paul T.; Farjah, Farhood; Fuchs, Charles S.; Gerdes, Hans; Gibson, Michael K.; Glasgow, Robert E.; Hayman, James A.; Hochwald, Steven N.; Hofstetter, Wayne L.; Ilson, David H.; Jaroszewski, Dawn E.; Johung, Kimberly L.; Keswani, Rajesh N.; Kleinberg, Lawrence; Korn, W. Michael; Leong, Stephen; Linn, Catherine; Lockhart, A. Craig; Ly, Quan P.; Mulcahy, Mary F.; Orringer, Mark B.; Perry, Kyle A.; Poultsides, George A.; Scott, Walter J.; Strong, Vivian E.; Washington, Mary Kay; Weksler, Benny; Willett, Christopher G.; Wright, Cameron D.; Zelman, Debra; McMillian, Nicole R.; Sundar, Hema

doi:10.6004/jnccn.2016.0137

Cited by 808 publications

(726 citation statements)

References 86 publications

(174 reference statements)

Supporting

Mentioning

705

Contrasting

Unclassified

Order By: Relevance

“…We adopted the rules of proper oncological resection of GA that include a minimum safety margin of 4 cm and D2 LN dissection [14]. Although the length of hospital stay in our study was longer in the open surgery group, the difference did not reach a statistical significance (7.2 vs 7.3 days; P = 0.86).…”

Section: Discussioncontrasting

confidence: 47%

“…Patients with tumors in the upper third of the stomach were also excluded as these patients will need more extensive resection in the form of subtotal or total gastrectomy and may need esophageal resection; techniques that need more complex steps during laparoscopy [12] [13]. For the same reason, we excluded patients with T4 tumors that invade the serosa and/or the surrounding structures [14].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Short Term Outcomes of Laparoscopic versus Open Distal Gastrectomy with D2 Lymph Nodes Dissection for Gastric Cancer: A Prospective Study

Abdelaziem¹,

El-Bakary²,

Allah³

2017

View full text Add to dashboard Cite

Background: Laparoscopic distal gastrectomy (LDG) for gastric adenocarcinoma (GA) is gaining more acceptances worldwide. Its results are still controversial. This study aimed to assess short term outcomes of LDG and compare it to the standard open distal gastrectomy. Patients and Methods: 27 patients with GA of the distal 2/3 of the stomach were included and divided into 2 groups; Group A: 15 patients submitted to open distal gastrectomy with D2 lymph node (LN) dissection, and Group B: 12 patients submitted to LDG with D2 LN dissection. Results: The median age was 54 and 54.3 years in group A and B respectively. The median operative time was 118.7 and 210.2 minutes in group A and B respectively. The median safety margin was 6.52 and 5.7 cm in group A and B respectively while the median number of excised LN was 24.2 and 21.4 in group A and B respectively. One patient in group B had intraoperative bleeding that was controlled laparoscopically. No conversion to open surgery needed in group B. The median number of narcotic doses was 5.9 and 4.25 in group A and B respectively. The median length of hospital stay was 7.2 days in group A and 7.3 days in group B. Three patients in group A and 2 patients in group B had postoperative complications and all were treated successfully conservatively. Conclusion: LDG with D2 LN dissection is oncologically safe with short-term outcomes comparable to those of the open surgery. Gaining more surgeons' experience is necessary to improve these results.

show abstract

Section: Discussioncontrasting

confidence: 47%

Section: Discussionmentioning

confidence: 99%

Short Term Outcomes of Laparoscopic versus Open Distal Gastrectomy with D2 Lymph Nodes Dissection for Gastric Cancer: A Prospective Study

Abdelaziem¹,

El-Bakary²,

Allah³

2017

View full text Add to dashboard Cite

show abstract

“…Therefore, cheap and convenient methods for early diagnoses of gastric cancer are badly needed which may improve the general prognosis of GC. The National Comprehensive Cancer Network (NCCN) gastric cancer guidelines describe several GC screening or early diagnosis procedures such as gastroscopy, barium meal test and other tests [12]. However, the highly expensive and relatively complex operating procedures make these methods unsuitable for screening on a population basis, particularly for asymptomatic subjects.…”

Section: Discussionmentioning

confidence: 99%

Increased miR-25 expression in serum of gastric cancer patients is correlated with CA19-9 and acts as a potential diagnostic biomarker

et al. 2017

View full text Add to dashboard Cite

AbstractObjectiveTo evaluate miR-25 expression in serum of gastric cancer (GC) patients and whether it can be a potential biomarker for GC diagnosis.MethodsForty one pathology confirmed GC patients and 41 healthy controls were included in this study. 10 mL peripheral venous blood were collected from GC patients and healthy controls. miR-25 relative expression and CA19-9 level in serum of GC patients and healthy controls were measured by real-time reverse transcription quantitative polymerase chain reaction (RT-qPCR) and enzyme linked immunosorbent assay (ELISA), respectively. The diagnostic sensitivity, specificity and receiver operating characteristic (ROC) curve of serum miR-25 and CA19-9 were calculated by STATA11.0 software.ResultsThe relative expression of miR-25 was 0.47±0.53 and 0.05±0.36 in serum of GC patients and healthy controls respectively with significant statistical difference (P<0.05). The serum level of CA19-9 for GC patients and healthy controls were 11.91±6.17 U/mL and 7.40±3.97 U/mL, indicating GC patients were much higher than those of healthy controls (P<0.05). The diagnostic sensitivity and specificity were 78.05% and 60.98% with the cut-off value of 0.32 for serum miR-25. Under this cut-off value, the area under the ROC curve was 0.75. For serum CA19-9, the diagnostic sensitivity and specificity were 70.73% and 56.10% with the cut-off value of 9.22 U/mL. Under this cut-off value, the area under the ROC curve was 0.73 with the 95% confidence interval of 0.62-0.84. Positive correlation was found between serum miR-25 relative expression and CA19-9 concentration of GC patients (r=0.75, P<0.05).ConclusionAccording to our present study, serum miR-25 was elevated in GC patients which may serve as a diagnostic biomarker for GC.

show abstract

“…The only chance for cure of non-metastatic OAC is complete resection. Perioperative chemotherapy improves OS in OAC patients with locoregional disease (3,5,17,18). However, as gastrectomy and particularly oesophagectomy are high-risk procedures, the patient's preoperative general condition is crucial for the success of the interdisciplinary therapy approach.…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature

et al. 2017

View full text Add to dashboard Cite

Abstract. Perioperative platinum/fluoropyrimidine-based chemotherapy is the therapeutic standard for oesophagogastric cancer (OAC) patients with locoregional disease. The preoperative condition directly affects postoperative prognosis; thus, particularly for elderly patients, a perioperative regimen with a favourable side effect profile is highly desirable. In the palliative setting, the combination of cisplatin and S-1 (Cis/S-1) was found to be as effective as cisplatin/5-fluorouracil, but with a more favourable side effect profile. However, no data on this combination have been reported in the perioperative setting in Caucasian patients. To the best of our knowledge, this is the first report on the treatment outcome of two elderly Caucasian OAC patients with locoregional disease receiving two neoadjuvant 4-week cycles of intravenous Cis/S-1. Both patients tolerated the doublet therapy well. No treatment delay or dose reduction was required. In both cases, preoperative staging revealed a clear response and complete surgical resection could be performed without any complications.

show abstract

Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology

Cited by 808 publications

References 86 publications

Short Term Outcomes of Laparoscopic versus Open Distal Gastrectomy with D2 Lymph Nodes Dissection for Gastric Cancer: A Prospective Study

Short Term Outcomes of Laparoscopic versus Open Distal Gastrectomy with D2 Lymph Nodes Dissection for Gastric Cancer: A Prospective Study

Increased miR-25 expression in serum of gastric cancer patients is correlated with CA19-9 and acts as a potential diagnostic biomarker

Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature

Contact Info

Product

Resources

About